AptarGroup, Inc. 10-Q Summary: Quarter Ended September 30, 2002
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2002, for AptarGroup, Inc., a Delaware corporation. The company operates in the packaging components industry, developing, manufacturing, and selling consumer product dispensing systems. Operations are organized into two reportable segments: Dispensing Systems (spray/lotion pumps, closures, aerosol valves) and SeaquistPerfect (aerosol valves and accessories). The company has significant international operations, with approximately 56% of third-quarter sales generated in Europe.
Key Financial Metrics
| Metric | Q3 2002 | Q3 2001 | YTD 9M 2002 | YTD 9M 2001 |
|---|---|---|---|---|
| Net Sales | $239.8 million | $221.6 million | $691.6 million | $686.3 million |
| Operating Income | $29.0 million | $27.3 million | $80.3 million | $84.3 million |
| Net Income | $17.8 million | $15.7 million | $48.6 million | $49.0 million |
| Diluted EPS | $0.49 | $0.43 | $1.32 | $1.34 |
| Operating Margin | 12.1% | 12.3% | 11.6% | 12.3% |
| Cash from Operations (9M) | $111.4 million (2002) vs $87.4 million (2001) | |||
| Cash & Equivalents | $76.1 million (Sep 30, 2002) vs $48.0 million (Dec 31, 2001) | |||
| Total Debt (Long-term + Current) | $241.4 million (Sep 30, 2002) vs $252.6 million (Dec 31, 2001) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8.2% in Q3 2002 compared to Q3 2001. However, "Core Sales" (excluding currency effects) increased only 4% in the quarter and decreased 1% year-to-date. Growth was driven by the personal care, food, and pharmaceutical markets, offset by a decline in the fragrance/cosmetic market.
- Margin Compression: Cost of sales as a percentage of net sales increased to 64.3% in Q3 2002 from 62.9% in Q3 2001. This was driven by rising material prices (LIFO impact), unfavorable currency translation on European costs, underutilized fixed costs due to lower fragrance/cosmetic sales, and a flood at a Czech Republic facility.
- Non-Recurring Items: The prior year (2001) included significant charges for a "Strategic Initiative" ($8.8 million YTD) and goodwill amortization ($2.7 million YTD). The current year (2002) included a $4.2 million patent dispute settlement in Q1 and minimal Strategic Initiative charges ($1.4 million YTD). Excluding these items, comparable operating income decreased $9.9 million YTD.
- Segment Performance: The SeaquistPerfect segment saw EBIT double in Q3 2002 compared to the prior year. The Dispensing Systems segment saw EBIT decline 1.4% in Q3 and 10.7% YTD, primarily due to the fragrance/cosmetic market weakness.
Guidance, Outlook, and Risks
- Outlook: Management expects diluted earnings per share for the full year 2002 to equal or slightly exceed the prior year's comparable basis of $1.87 (excluding 2002 special charges and 2001 goodwill amortization/Strategic Initiative costs).
- Market Trends: The anticipated recovery in the fragrance/cosmetic market has not yet materialized. Incoming orders in Q3 showed slight improvement but do not indicate a Q4 turnaround. Pharmaceutical sales are expected to decrease slightly in Q4 from strong 2001 levels, while personal care, household, and food markets are expected to increase.
- Liquidity: The company maintains a $100 million revolving credit facility with $27 million available as of September 30, 2002. Net debt to total net capitalization decreased to 23.2% from 30.4% at year-end 2001.
- Risks: Key risks include foreign currency fluctuations (primary exposure to the Euro), rising insurance costs, raw material price volatility, and the failure to achieve anticipated cost savings from the Strategic Initiative. A flood at a Czech facility caused production delays and cleanup expenses.
Investor Verification Checklist
- Core Sales Trend: Verify the divergence between reported sales growth (driven by currency) and core sales decline in the fragrance/cosmetic sector.
- Cost Structure: Assess the sustainability of the increased cost of sales (64.3%) due to LIFO impacts and underutilized capacity.
- Comparable Earnings: Review the "Operating Income Excluding Non-recurring Charges" table to understand underlying operational performance versus reported GAAP results.
- Strategic Initiative Completion: Confirm the status of the $11.1 million Strategic Initiative, noting that approximately $11.0 million has been expensed as of September 30, 2002.
- Currency Exposure: Evaluate the impact of the Euro/U.S. Dollar exchange rate on both translation gains and transaction costs for European-sourced products sold in the U.S.